US Oncologist Survey: Optimizing Treatment for Metastatic Clear Cell Renal Cell Carcinoma

Date: February 22, 2011
Pages: 29
Price:
US$ 2,499.00 US$ 500.00
License [?]:
Publisher: The Assessment Group
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery
ID: UD73379F728EN
Leaflet:

Download PDF Leaflet

US Oncologist Survey: Optimizing Treatment for Metastatic Clear Cell Renal Cell Carcinoma
Specific patient case scenario that unfolds throughout the report, presented to high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their clinical decisions. Out of 174 oncologists’ responses, those who use combination chemotherapy were most likely to use xx and xx. Oncologists who use a single agent were most likely to use x or x. Key factors in the choice of therapy include the following….

Patient specific case scenario that unfold throughout the report, presented to 174 high-prescribing oncologists on Triple Positive Metastatic Breast Cancer for their open responses on clinical decisions. Patient progression reveals:

Patient specific case scenarios that unfold throughout the report, presented to 174 high-prescribing oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer for their open responses on clinical decisions, distributed and collected December 15, 2010 and January 10, 2011. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment.

Two patient specific case scenarios that unfold throughout the report, presented to 119 high-prescribing oncologists on Metastatic Clear Cell Renal Cell Cancer for their open responses on clinical decisions. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment. Patients include:

Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US Oncologists on the treatment of patients with advanced prostate cancer.

Case highlights include:
  • Rising PSA in a patient without documented metastatic disease
  • Asymptomatic castration resistant metastatic disease
  • Symptomatic metastatic disease
  • Symptomatic disease in an elderly patient
Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists’ decisions. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:
  • Understand what occurs with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing and improving your market strategies
  • Pinpoint needs of your target audience
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your product fits
  • Understand where your competitor’s product fits
  • Design messages to advance brand performance
Executive Summary

CHAPTER 1: INTRODUCTION

Table 1. Treatment Options in Renal Cell Cancer

CHAPTER 2. SURVEY RESPONDENT DEMOGRAPHICS

Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State’s Renal Cell Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

CHAPTER 3: TREATMENT OF AN ELDERLY PATIENT WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA

Figure 3.1 Treatment Regimen Chosen Following Surgery
Figure 3.2 Adding Therapeutic Agents with Initial Treatment
Figure 3.3 Treatment Decision for Medication Toxicity
Figure 3.4 Second-Line Therapy
Figure 3.5 Factors Influencing Treatment
Figure 3.6 Confidence in Managing Clear Cell Renal Cell Carcinoma
Figure 3.8 Most Important Barrier to Optimal Patient Management

CHAPTER 4: TREATMENT OF A PATIENT WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA WITH COMORBIDITIES

Figure 4.1 Management of Patient with Metastatic Disease and Comorbidities
Figure 4.2 Choice of Systemic Therapy Agent
Figure 4.3 Test to Monitor to Evaluate Increased Fatigue with Pazopanib
Figure 4.4 Next Systemic Treatment Choice for Progressive Disease

CHAPTER 5: SUMMARY

Appendix A: Survey Instrument
Figure 5.1 Barriers to optimal treatment
Figure 5.2 Confidence in treating to optimal outcome
Figure 5.3 Treatment following rising PSA on leuprolide
Figure 5.4 Treatment decision upon disease progression
Figure 5.5 Factors that influenced treatment
Table 1 Factors that influenced treatment by chosen agent
Figure 5.6 Other agents that would be appropriate to include in therapy
Figure 5.6 Treatment upon rising PSA
Figure 5.7 Treatment upon further disease progression

CHAPTER 6: PATIENT WITH GLEASON’S 3+4 ADENOCARCINOMA AND MULTIPLE METASTASES TO PELVIS AND SPINE DEVELOPS CASTRATION-RESISTANT DISEASE.

Figure 6.1 Appropriate Treatment
Figure 6.2 Confidence in treating to optimal outcome
Figure 6.3 Continuation of LHRH agonist
Figure 6.4 Factors Associated with Continuing LHRH Agonist
Figure 6.5 Cycles of docetaxel that the patient should receive
Figure 6.6 Next therapy with good performance status upon progressing after docetaxel

CHAPTER 7: ELDERLY PATIENT WITH GLEASON’S 5+5 AND MULTIPLE METASTASES

Figure 6.1 Treatment of patient
Figure 6.2 Confidence in treating to optimal outcome
Figure 6.3 Treatment of patient’s progressive disease

CHAPTER 8: SUMMARY

Appendix A: Survey Instrument
Skip to top


Ask Your Question

US Oncologist Survey: Optimizing Treatment for Metastatic Clear Cell Renal Cell Carcinoma
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: